Skip to main content
< Back to news
INBRAIN BCI Cortical Film. Image / INBRAIN Neuroelectronics
 16.09.2025

INBRAIN Neuroelectronics opens U.S. office and announces collaboration with Mayo Clinic to advance its brain-computer interface

INBRAIN Neuroelectronics, a company developing brain-computer interface (BCI-Tx) therapies, headquartered at the Barcelona Science Park (PCB), is expanding its presence in the United States with the creation of a subsidiary in Boston that will serve as the operations hub for clinical trials in the country and the future commercialization of its innovative graphene-based neural interface. As part of this internationalization process, the medical technology company has also signed a collaboration agreement with Mayo Clinic to accelerate the development and market entry of INBRAIN’s precision BCI-Tx therapies, aimed at patients with unmet needs in neurological disorders.

Within the framework of this alliance, specialists from INBRAIN and Mayo Clinic will engage in a non-exclusive know-how exchange that will enable the practical evaluation of INBRAIN’s investigational BCI-Tx platform in IRB-approved environments. The goal is to generate high-quality clinical evidence in shorter timelines.

“Our objective is to translate the unique performance of graphene and artificial intelligence into benefits for patients and healthcare professionals,” said Carolina Aguilar, CEO and co-founder of INBRAIN Neuroelectronics. “With Mayo Clinic’s clinical know-how, alongside other leading U.S. and European centers, we aim to validate our platform in real-world workflows, accelerate evidence generation, and responsibly advance toward patient-centered BCI therapeutics.”

In addition to the new Boston office, which will serve as a hub for clinical trials and the foundation for the company’s therapeutic expansion beyond Parkinson’s disease, INBRAIN also plans to establish another site on the U.S. West Coast, while maintaining its global headquarters and R&D activities in Barcelona. At the same time, the company is advancing scalable manufacturing processes for its graphene-based BCI, with the goal of enabling broader clinical and commercial adoption worldwide.

To date, INBRAIN has raised $124 million in funding from an international consortium of medtech and deeptech investors, including Aliath Bioventures, Asabys Partners, CDTI, Government of Catalonia (Avançsa & ICF), FondICO, Graybella Capital, IMECXpand, Mayo Clinic, the European Innovation Council, Truventuro, and Vsquared Ventures.

Mayo Clinic maintains a financial interest in the technology mentioned in this release. Any revenue it receives will be used to support its non-profit mission in patient care, research, and education.

» Link to the news [+]